Zetia Cost in Connecticut 2026: Cash Price, Medicaid, Insurance and Compounded Options

What Does Zetia Actually Cost in Connecticut Right Now?

Brand Zetia and generic ezetimibe sit at opposite ends of the price spectrum in Connecticut. The Merck brand list price is approximately $380 per month, but the generic 10 mg tablet averages roughly $15 per month at Connecticut retail pharmacies when a free discount card is applied. Patients who qualify for a 503A compounded preparation may pay nothing out of pocket.

Brand-name Zetia (ezetimibe 10 mg, manufactured by Merck) received FDA approval in 2002 and remains on the market alongside multiple FDA-approved generics. The FDA label for ezetimibe confirms the approved indication: reducing LDL-C as an adjunct to diet, alone or with a statin. Because the brand carries a $380 list price and generics are therapeutically equivalent, most prescribers in Connecticut write "dispense as written generic permissible" on their pads by default.

Prices across Connecticut retail chains, independent pharmacies, and mail-order services in 2026 vary by ZIP code, but the national average for generic ezetimibe 10 mg hovers near $15 to $20 for a 30-day supply when a coupon is applied at pharmacies including CVS, Walgreens, Stop and Shop Pharmacy, and RiteAid locations throughout Hartford, New Haven, Stamford, Bridgeport, and Waterbury. Without any coupon, the same generic may ring up between $35 and $80 depending on the dispensing pharmacy's usual-and-customary price, which is why presenting a GoodRx, RxSaver, or NeedyMeds card at the counter matters even for insured patients whose plan tier places ezetimibe on Tier 3.

A 90-day mail-order supply through most PBM-administered plans cuts the per-unit cost further. Patients enrolled in a commercial plan that places generic ezetimibe on Tier 1 or Tier 2 may pay $0 to $10 per 90-day fill through their plan's preferred mail pharmacy.

How Connecticut Medicaid (HUSKY Health) Covers Ezetimibe

Connecticut Medicaid, branded HUSKY Health, covers ezetimibe with prior authorization (PA). The PA requirement is not automatic denial; it is a clinical documentation step that confirms the prescriber has documented elevated LDL-C, dietary intervention, and typically a statin trial or statin intolerance before stand-alone ezetimibe is approved. IMPROVE-IT (N=18,144) published in the NEJM in 2015 demonstrated that adding ezetimibe to simvastatin reduced the composite cardiovascular endpoint by 6.4% relative risk reduction over seven years, which gave payers, including state Medicaid programs, the outcomes data needed to justify coverage.

Once the PA is approved, HUSKY Health members generally pay $0 to $3 per fill depending on their specific HUSKY plan tier (HUSKY A, C, or D). Managed care organizations (MCOs) contracted with CT DSS, including Aetna Better Health of CT, Anthem HealthKeepers, and Community Health Network of Connecticut, each maintain their own formularies, but all are required to cover at least one ezetimibe product on their HUSKY formulary under state drug benefit rules.

To obtain a PA for ezetimibe under HUSKY Health, the prescribing clinician typically must document:

1. A diagnosis of primary hypercholesterolemia (ICD-10 E78.00 or E78.5) or mixed hyperlipidemia (E78.2).
2. An LDL-C level above the patient's risk-stratified target despite diet modification.
3. Either current statin therapy (with ezetimibe as add-on) or documented statin intolerance, adverse effects, or contraindication justifying stand-alone ezetimibe.
4. Absence of a clinical reason to prefer a PCSK9 inhibitor first.

The PA approval period is typically 12 months and renewable annually with a repeat lipid panel demonstrating response or continued medical necessity.

Is Compounded Ezetimibe Legal in Connecticut?

Compounded ezetimibe is legal in Connecticut when prepared by a licensed 503A pharmacy operating in compliance with state and federal law. The cost to the patient in qualifying situations may be $0 per month.

Under federal law, Section 503A of the Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare patient-specific formulations from bulk active pharmaceutical ingredients (APIs) when a valid patient-specific prescription exists and when the commercially available product is not clinically appropriate for the individual patient. Connecticut's Department of Consumer Protection (DCP) Pharmacy Commission licenses and inspects 503A compounding pharmacies operating within state lines. Out-of-state 503A pharmacies shipping into Connecticut must hold a Connecticut non-resident pharmacy permit.

A common scenario where compounded ezetimibe is prescribed: a patient cannot swallow standard tablets (dysphagia, pediatric dosing, or GI conditions requiring liquid formulation) and no FDA-approved oral liquid exists. In that case, a 503A pharmacy may compound a suspension or alternative dose form under the prescribing clinician's direction. The FDA's guidance on 503A compounding facilities clarifies the legal framework.

One point patients sometimes misread: compounded ezetimibe is NOT a shortcut around a prescription requirement. A valid, patient-specific prescription from a Connecticut-licensed or telehealth-licensed prescriber is still required. Compounding is also not interchangeable with a commercially available tablet solely for cost reasons under federal law, though state Medicaid programs and commercial plans may cover compounded versions if medically justified and the 503A pharmacy is in-network.

The "$0/month" cost figure associated with compounded ezetimibe in some Connecticut programs reflects certain telehealth clinic structures where the compounding pharmacy fee is bundled into a membership or provider visit fee, not that the drug itself is being dispensed at no cost to any regulatory body.

Which Insurance Plans Cover Zetia in Connecticut?

Most commercial insurance plans in Connecticut cover generic ezetimibe on formulary, typically at Tier 2 or Tier 3. Brand Zetia is on Tier 4 or Tier 5 at most plans, making the generic the clinically and financially preferred option for the vast majority of Connecticut patients.

Major insurers with substantial Connecticut commercial enrollment, including Anthem Blue Cross Blue Shield of CT, Aetna (also headquartered in Hartford), ConnectiCare, Harvard Pilgrim Health Care, and UnitedHealthcare, all list generic ezetimibe 10 mg on their 2026 formularies. The tier placement determines your copay:

• Tier 1 preferred generic: $0 to $10 per 30-day fill
• Tier 2 non-preferred generic: $15 to $40 per 30-day fill
• Tier 3 preferred brand: $45 to $90 per 30-day fill
• Tier 4 non-preferred brand (brand Zetia): $80 to $150+ per 30-day fill

Patients on Medicare Part D plans sold in Connecticut follow CMS formulary tiers, which changed significantly under the Inflation Reduction Act drug price negotiation framework. Starting in 2026, out-of-pocket drug costs for Medicare Part D beneficiaries are capped at $2,000 annually, which meaningfully limits maximum annual exposure even if ezetimibe sits on a higher tier. CMS has described these changes in detail in the IRA implementation guidance.

To confirm your exact copay in Connecticut, log into your plan's member portal and use the formulary drug lookup tool. Entering "ezetimibe" (not "Zetia") returns the generic tier placement, prior authorization requirements, and step therapy requirements for your specific plan year and enrollment type.

Getting Zetia or Ezetimibe via Telehealth in Connecticut

Prescribing ezetimibe via telehealth is fully legal in Connecticut. A telehealth visit with a Connecticut-licensed or appropriately registered out-of-state prescriber can generate a valid ezetimibe prescription, which can then be sent to any licensed Connecticut pharmacy or a mail-order pharmacy serving Connecticut.

Connecticut enacted telehealth parity law under Conn. Gen. Stat. Section 38a-499b, requiring that commercial insurers reimburse covered telehealth services at rates comparable to in-person visits. This means the prescriber visit cost for an asynchronous or synchronous telehealth consultation should be covered at your standard specialist or primary care copay rate if ezetimibe prescribing falls within the scope of that visit.

For patients whose primary lipid management is straightforward (documented LDL-C, stable cardiovascular risk profile, no new symptoms), a telehealth visit is clinically sufficient to initiate, continue, or adjust ezetimibe therapy. The prescriber will typically review a recent lipid panel (within 3 to 12 months), assess cardiovascular risk using the ACC/AHA Pooled Cohort Equations or equivalent, and confirm the absence of known contraindications. The ACC/AHA 2018 guideline on blood cholesterol management recommends ezetimibe as a first-line add-on to statins when LDL-C remains above 70 mg/dL in very high-risk patients.

Telehealth platforms operating in Connecticut include both national services and CT-specific practices. HealthRX clinicians can evaluate your lipid panel and determine whether ezetimibe (brand, generic, or compounded formulation) is appropriate, then route the prescription to your preferred Connecticut pharmacy.

The Clinical Case for Ezetimibe: Why Patients and Clinicians Choose It

Ezetimibe works by a mechanism distinct from statins. It inhibits the NPC1L1 transporter at the intestinal brush border, reducing cholesterol absorption by approximately 50%. This produces an average LDL-C reduction of 18% to 25% as monotherapy and roughly an additional 25% LDL-C reduction when added to maximally tolerated statin therapy. A Cochrane systematic review of ezetimibe trials confirmed these lipid-lowering magnitudes across multiple randomized controlled trials.

The cardiovascular outcomes data come primarily from IMPROVE-IT. In that trial, 18,144 patients with recent acute coronary syndrome were randomized to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. After a median follow-up of six years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm (P<0.001). The primary composite endpoint (cardiovascular death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke) occurred in 32.7% of the combination group versus 34.7% of the placebo group, a statistically significant 2.0 percentage point absolute risk reduction. The full IMPROVE-IT results are published in NEJM.

As the IMPROVE-IT investigators concluded: "The addition of ezetimibe to statin therapy resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes." This is the landmark statement that justified ezetimibe's position in the ACC/AHA guideline as a recommended second-line lipid-lowering agent.

Ezetimibe is particularly favored for patients who:

• Cannot tolerate higher doses of statins due to myopathy or elevated transaminases
• Require LDL-C reduction below what maximally tolerated statin therapy achieves alone
• Have sitosterolemia, a rare genetic disorder for which ezetimibe is first-line
• Need LDL-C lowering during pregnancy workup planning where some other agents are contraindicated (prescribers should review individual risk-benefit; FDA Category data applies)

The drug is generally well tolerated. The most common adverse effects reported in clinical trials are upper respiratory infections (4.3%), diarrhea (4.1%), arthralgia (3.0%), and sinusitis (2.8%), none of which exceeded placebo rates by a clinically meaningful margin in IMPROVE-IT.

Connecticut-Specific Ezetimibe Savings Programs and Discount Cards

Multiple savings mechanisms are available to Connecticut residents paying for ezetimibe out of pocket or managing high copays. Here is a practical breakdown.

Manufacturer Savings Card (Merck for brand Zetia). Merck offers a savings card for commercially insured patients (not valid for Medicaid or Medicare). In 2026, the card may reduce brand Zetia out-of-pocket cost to $0 to $25 per month for eligible patients. The card is available at ZetiaHCP.com or through a prescriber's office. Income verification is not required for commercially insured patients. Connecticut Medicaid or Medicare Part D patients are not eligible under federal anti-kickback statute rules.

GoodRx, RxSaver, NeedyMeds, and similar discount services. These are free to use at Connecticut pharmacies and consistently bring generic ezetimibe 10 mg to $10 to $18 per 30-day supply. Presenting the coupon card or mobile app code at the pharmacy counter bypasses your insurance copay tier. This may actually be cheaper than your insurance copay if ezetimibe sits on Tier 3 or Tier 4 of your plan.

Merck Patient Assistance Program (Merck Helps). For uninsured or underinsured Connecticut residents who meet income criteria (generally at or below 400% of the federal poverty level), the Merck Helps program may provide brand Zetia at no cost. Applications are processed through the prescriber's office or directly at Merck.com/en/patient-assistance-program.

Connecticut State Pharmaceutical Assistance Program (ConnPACE / CHOICES). ConnPACE has historically provided drug cost assistance to Connecticut seniors and people with disabilities not fully covered by Medicare Part D. As of 2026, eligibility and benefit levels should be verified directly with the Connecticut Department of Social Services, as program parameters change annually with state budget cycles.

The table below represents the HealthRX Connecticut Ezetimibe Cost Decision Framework, a structured approach our clinical team uses to route patients to the lowest appropriate cost pathway:

Step 1. Confirm whether the patient has CT Medicaid (HUSKY): If yes, submit PA and aim for $0 to $3 copay. Step 2. If commercially insured, check plan formulary tier for generic ezetimibe. If Tier 1 or 2, use insurance. If Tier 3 or 4, compare coupon price. Step 3. If uninsured, apply GoodRx or equivalent coupon for ~$15 cash price, or assess Merck Helps eligibility. Step 4. If medical necessity for compounded formulation exists (dysphagia, pediatric dosing, documented intolerance to excipients), route to licensed 503A compounding pharmacy in Connecticut. Step 5. If cost remains a barrier after Steps 1 through 4, check ConnPACE or CHOICES eligibility and consider 90-day mail-order to reduce per-unit cost.

Comparing Ezetimibe to Other LDL-Lowering Options in Connecticut

Ezetimibe's cost profile becomes clearer when placed alongside alternatives. Statins like atorvastatin 40 mg are available for $4 to $10 per month in Connecticut, making them the lowest-cost first-line option. Ezetimibe at $15/month as a generic is a reasonable add-on.

PCSK9 inhibitors (evolocumab, alirocumab) carry list prices of $6,000 to $7,000 per year and require step therapy documentation demonstrating statin plus ezetimibe failure or intolerance before most Connecticut plans approve them. Inclisiran, the twice-yearly injectable, has a similar price ceiling. Bempedoic acid (Nexletol) and the fixed-dose combination with ezetimibe (Nexlizet) are newer oral options covered on some Connecticut formularies at Tier 3, with list prices around $3,400 per year.

For most Connecticut patients with elevated LDL-C who are already on maximally tolerated statin therapy, generic ezetimibe at $15/month remains the most cost-effective next step before escalation to PCSK9 inhibition. The ACC/AHA 2018 cholesterol guideline states that in patients with clinical ASCVD and LDL-C above 70 mg/dL on maximally tolerated statin, "it is reasonable to add ezetimibe to maximally tolerated statin therapy" (Class IIa, Level of Evidence: B-R).

What to Bring to Your Connecticut Prescriber or Telehealth Visit

Getting an ezetimibe prescription efficiently, whether in person at a Connecticut clinic or via telehealth, depends on having the right documentation ready. A recent lipid panel (ideally within 6 months) showing your LDL-C, HDL-C, total cholesterol, and triglycerides is the single most important item. The prescriber also needs your current medication list to screen for interactions, your cardiovascular history (prior MI, stroke, or coronary artery disease raises your risk class and strengthens the clinical case for aggressive LDL-C targets), and documentation of any statin intolerance if ezetimibe is being considered as monotherapy.

Lab work done at any Connecticut Quest Diagnostics, LabCorp, Yale New Haven Health, Hartford HealthCare, or hospital outpatient lab can be uploaded directly to a telehealth platform. Connecticut joined the CommonWell Health Alliance network, so records from most major Connecticut health systems are shareable electronically, which simplifies the telehealth prescribing workflow.

A standard telehealth visit for lipid management at HealthRX runs approximately 15 to 20 minutes. The prescriber reviews your labs, calculates your 10-year ASCVD risk using the Pooled Cohort Equations, and determines the appropriate LDL-C target. If ezetimibe is indicated, the prescription goes to your chosen Connecticut pharmacy that same day.